[go: up one dir, main page]

PA8487201A1 - Moduladores de ccr5 - Google Patents

Moduladores de ccr5

Info

Publication number
PA8487201A1
PA8487201A1 PA19998487201A PA8487201A PA8487201A1 PA 8487201 A1 PA8487201 A1 PA 8487201A1 PA 19998487201 A PA19998487201 A PA 19998487201A PA 8487201 A PA8487201 A PA 8487201A PA 8487201 A1 PA8487201 A1 PA 8487201A1
Authority
PA
Panama
Prior art keywords
ccr5
modulators
treatment
ccr5 modulators
retrovent
Prior art date
Application number
PA19998487201A
Other languages
English (en)
Inventor
Duncan Robert Armour
David Anthony Price
Anthony Wood
Manoussos Perros
Blanda Luzia Christa Stammen
Martin Paul Edwards
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9921375.3A external-priority patent/GB9921375D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8487201A1 publication Critical patent/PA8487201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS COMPUESTOS QUIMICOS, ESPECIALMENTE A COMPUESTOS FARMACEUTICOS COMO MODULADORES DE CCR5, PARA EL TRATAMIENTO DE ENFERMEDADES Y AFECCIONES ANTIINFLAMATORIAS Y EL TRATAMIENTO Y PREVENCION DE INFECCIONES PRODUCIDAS POR VIH-1 Y POR RETROVIRUS RELACIONADOS GENETICAMENTE
PA19998487201A 1998-12-23 1999-12-10 Moduladores de ccr5 PA8487201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9921375.3A GB9921375D0 (en) 1999-09-10 1999-09-10 CCR5 Modulators

Publications (1)

Publication Number Publication Date
PA8487201A1 true PA8487201A1 (es) 2002-02-21

Family

ID=26314899

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998487201A PA8487201A1 (es) 1998-12-23 1999-12-10 Moduladores de ccr5

Country Status (48)

Country Link
US (1) US6586430B1 (es)
EP (1) EP1140085B1 (es)
JP (1) JP3602795B2 (es)
KR (1) KR100425612B1 (es)
CN (1) CN1331591A (es)
AP (1) AP1697A (es)
AR (1) AR024233A1 (es)
AT (1) ATE505190T1 (es)
AU (1) AU763644B2 (es)
BG (1) BG65448B1 (es)
BR (1) BRPI9917007B8 (es)
CA (1) CA2350073C (es)
CO (1) CO5300387A1 (es)
CR (2) CR6392A (es)
CU (1) CU23344A3 (es)
CY (1) CY1111504T1 (es)
CZ (1) CZ300926B6 (es)
DE (1) DE69943352D1 (es)
DK (1) DK1140085T3 (es)
DZ (2) DZ2979A1 (es)
EA (1) EA004988B1 (es)
EE (1) EE05170B1 (es)
EG (1) EG24400A (es)
GC (1) GC0000117A (es)
GE (1) GEP20033131B (es)
HK (1) HK1039902A1 (es)
HR (2) HRP20120132B1 (es)
HU (1) HU228754B1 (es)
ID (1) ID28965A (es)
IL (2) IL143512A0 (es)
IS (1) IS5944A (es)
MA (1) MA26714A1 (es)
ME (1) ME00513B (es)
NO (1) NO330677B1 (es)
NZ (1) NZ511794A (es)
OA (1) OA11735A (es)
PA (1) PA8487201A1 (es)
PE (1) PE20001420A1 (es)
PL (1) PL201875B1 (es)
PT (1) PT1140085E (es)
RS (1) RS51701B (es)
SI (1) SI1140085T1 (es)
SK (1) SK287020B6 (es)
TN (1) TNSN99252A1 (es)
TR (1) TR200101793T2 (es)
TW (1) TW577888B (es)
UA (1) UA72750C2 (es)
WO (1) WO2000038680A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1118858A3 (en) * 2000-01-12 2003-07-09 Pfizer Limited Assay method
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
IL152531A0 (en) * 2000-05-26 2003-05-29 Pfizer Tropane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AR041786A1 (es) * 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
JP3793200B2 (ja) * 2002-04-08 2006-07-05 ファイザー・インク Ｃｃｒ５モジュレータとしてのトロパン誘導体
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
DE60318891T2 (de) 2002-12-13 2009-01-22 Smithkline Beecham Corp. Cyclopropylverbindungen als ccr5 antagonisten
CA2509711A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
DE602004006424T2 (de) * 2003-07-31 2008-05-15 Astrazeneca Ab Piperidinderivate als ccr5-rezeptormodulatoren
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
GB0323236D0 (en) * 2003-10-03 2003-11-05 Pfizer Ltd Chemical compounds
US7309790B2 (en) * 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CA2720312A1 (en) * 2004-01-30 2005-08-18 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US20080132549A1 (en) * 2004-04-14 2008-06-05 Pfizer Inc. Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
JP4894518B2 (ja) 2004-09-13 2012-03-14 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AU2006233884A1 (en) * 2005-04-08 2006-10-19 Neurosearch A/S (+) - and (-) -8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicycl (3.2.1.)oct-2-ene
CA2603204A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
WO2007105637A1 (ja) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US20080015835A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20080015787A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
CA2673566A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
TWI448289B (zh) 2007-08-31 2014-08-11 Purdue Pharma Lp 經取代之喹啉型哌啶化合物及其用途
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8592395B2 (en) 2009-07-24 2013-11-26 Glaxosmithkline Llc Therapeutic compounds
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
WO2012122499A2 (en) 2011-03-09 2012-09-13 Pestell Richard G Prostate cancer cell lines, gene signatures and uses thereof
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2861302A4 (en) 2012-05-14 2016-08-24 Prostagene Llc USE OF CCR5 MODULATORS IN THE TREATMENT OF CANCER
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US20210268070A1 (en) * 2018-07-10 2021-09-02 Rush University Medical Center Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds
IL295400A (en) 2020-02-19 2022-10-01 Ichilov Tech Ltd Improved treatment for depression
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2021257420A1 (en) * 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors
WO2025064788A2 (en) * 2023-09-20 2025-03-27 Cidara Therapeutics, Inc. Ccr5 conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
PH30413A (en) 1992-03-26 1997-05-09 Boehringer Ingelheim Italia Crystalline forms of endo-2,3-dihydro-n-(8-methyl)-8-azabicyclo-(3,2,1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
SK1296A3 (en) * 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
SK113998A3 (en) * 1996-03-29 2001-05-10 Pfizer 6-phenylpyridyl-2-amine derivatives
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2000516210A (ja) * 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
WO1998004554A1 (en) * 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
JP2001508798A (ja) 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AU9206798A (en) 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
CA2318088A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
BRPI9917007B8 (pt) 2021-05-25
NO330677B1 (no) 2011-06-06
CA2350073A1 (en) 2000-07-06
RS51701B (sr) 2011-10-31
US6586430B1 (en) 2003-07-01
EE05170B1 (et) 2009-06-15
EP1140085A1 (en) 2001-10-10
JP3602795B2 (ja) 2004-12-15
CA2350073C (en) 2007-04-17
NO20013183D0 (no) 2001-06-25
AU763644B2 (en) 2003-07-31
HRP20120132B1 (hr) 2018-01-26
CR6392A (es) 2006-08-09
OA11735A (en) 2005-05-12
IL143512A (en) 2013-06-27
HRP20010468B1 (hr) 2012-06-30
PE20001420A1 (es) 2000-12-18
BRPI9917007B1 (pt) 2016-07-26
NZ511794A (en) 2003-10-31
SI1140085T1 (sl) 2011-08-31
DZ3326A1 (fr) 2005-05-29
EP1140085B1 (en) 2011-04-13
PT1140085E (pt) 2011-06-16
DZ2979A1 (fr) 2005-01-30
AP2001002186A0 (en) 2001-06-30
CO5300387A1 (es) 2003-07-31
HRP20010468A2 (en) 2003-02-28
HK1039902A1 (zh) 2002-05-17
SK287020B6 (sk) 2009-09-07
BG65448B1 (bg) 2008-08-29
EA004988B1 (ru) 2004-10-28
CU23344A3 (es) 2009-02-20
HUP0104795A3 (en) 2002-05-28
HUP0104795A2 (hu) 2002-04-29
TNSN99252A1 (fr) 2005-11-10
CZ20012298A3 (cs) 2002-09-11
JP2002533393A (ja) 2002-10-08
IS5944A (is) 2001-05-15
ATE505190T1 (de) 2011-04-15
GC0000117A (en) 2005-06-29
PL349495A1 (en) 2002-07-29
MA26714A1 (fr) 2004-12-20
DE69943352D1 (de) 2011-05-26
ME00513B (me) 2011-10-10
NO20013183L (no) 2001-08-08
CZ300926B6 (cs) 2009-09-09
HRP20120132A8 (hr) 2017-11-03
SK8752001A3 (en) 2003-02-04
EE200100345A (et) 2002-12-16
CR9879A (es) 2008-06-20
KR20010089701A (ko) 2001-10-08
ID28965A (id) 2001-07-19
EA200100589A1 (ru) 2002-02-28
CY1111504T1 (el) 2015-08-05
DK1140085T3 (da) 2011-06-27
CN1331591A (zh) 2002-01-16
UA72750C2 (en) 2005-04-15
PL201875B1 (pl) 2009-05-29
EG24400A (en) 2009-04-29
HU228754B1 (en) 2013-05-28
HRP20120132A2 (hr) 2012-03-31
TW577888B (en) 2004-03-01
YU38801A (sh) 2005-06-10
KR100425612B1 (ko) 2004-04-01
BR9917007A (pt) 2001-10-30
WO2000038680A1 (en) 2000-07-06
BG105721A (en) 2002-02-28
AR024233A1 (es) 2002-09-25
TR200101793T2 (tr) 2001-12-21
IL143512A0 (en) 2002-04-21
GEP20033131B (en) 2003-12-25
AU1675100A (en) 2000-07-31
AP1697A (en) 2006-12-22

Similar Documents

Publication Publication Date Title
PA8487201A1 (es) Moduladores de ccr5
PA8488101A1 (es) Moduladores de ccr5
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
PA8623001A1 (es) Compuestos de quinolina sustituidos
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
MXPA02011891A (es) Reacciones de adicion conjugadas para la entrega controlada de compuestos farmaceuticamente activos.
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
SV2003001107A (es) Imidazotriazinas ref.lea 35368
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
UY28945A1 (es) Derivados de pirrolopiridina
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
ATE405568T1 (de) Cytotoxische mittel
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
UY29161A1 (es) Nuevos heterociclos
GT200100169A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2.
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
AR026911A1 (es) Preparado farmaceutica para el tratamiento de afecciones tumorales
HN2003000104A (es) Derivados de ciclopenteno